Arbutus Biopharma Logo
Tekmira's LNP Technology Enables Alnylam's ALN-TTR01 Clinical Data
10 mai 2012 09h56 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, May 10, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today reported...
Arbutus Biopharma Logo
Tekmira Conference Call and Webcast Advisory: Corporate Update and First Quarter 2012 Results
09 mai 2012 16h47 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, May 9, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that it...
Arbutus Biopharma Logo
Tekmira's LNP Technology Enables Alnylam's Positive ALN-PCS Clinical Data
20 avr. 2012 10h51 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, April 20, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today reported...
Arbutus Biopharma Logo
Tekmira Provides Corporate Update and Announces 2011 Results
27 mars 2012 16h01 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 27, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced its...
Arbutus Biopharma Logo
Tekmira Provides Periodic Update to Shareholders Regarding Litigation
26 mars 2012 08h00 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 26, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today provided...
Arbutus Biopharma Logo
Tekmira Conference Call and Webcast Advisory: Corporate Update and 2011 Audited Results
22 mars 2012 16h40 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 22, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that...
Arbutus Biopharma Logo
Tekmira Provides Update on Licensed Product Candidate, Marqibo(R)
22 mars 2012 01h17 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 22, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, disclosed...
Arbutus Biopharma Logo
Tekmira Provides Update on Progress in USPTO Patent Interference Proceedings
15 mars 2012 00h50 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 15, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, disclosed that...
Arbutus Biopharma Logo
Tekmira Files Motion to Dismiss in Patent Infringement Suit
06 mars 2012 08h00 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 6, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, disclosed that...
Arbutus Biopharma Logo
Tekmira Expands Product Pipeline With RNAi Therapeutic for the Treatment of Alcohol Dependence
01 mars 2012 08h00 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 1, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...